Literature DB >> 438170

Metabolism of pyrazolo(3,4-d)pyrimidines in Leishmania braziliensis and Leishmania donovani. Allopurinol, oxipurinol, and 4-aminopyrazolo(3,4-d)pyrimidine.

D J Nelson, C J Bugge, G B Elion, R L Berens, J J Marr.   

Abstract

Leishmania donovani and Leishmania braziliensis grown in culture formed millimolar concentrations of allopurinol ribonucleoside 5'-monophosphate from [6-14C]allopurinol. In addition, allopurinol 1-ribonucleoside, oxipurinol riboside 5'-monophosphate, and three new metabolites of allopurinol, namely, 4-aminopyrazolo(3,4-d)pyrimidine ribonucleoside 5'-monophosphate and the corresponding di- and triphosphates (1-ribosyl 4-aminopyrazolo(3,4-d)pyrimidine 5'-diphosphate and 1-ribosyl 4-aminopyrazolo(3,4-d)pyrimidine 5'-triphosphate) were identified in the parasitic cells. They were formed via a unique amination reaction from 1-ribosyl allopurinol 5'-phosphate, analogous to the conversion of IMP to AMP. [6-14C]Allopurinol was incorporated into RNA of L. donovani in the form of 4-aminopyrazolo(3,4-d)pyrimidine. Adenine reversed the growth inhibition of allopurinol and prevented its metabolism to all of the ribonucleotide metabolites. L. donovani was 2- to 4-fold more active in its metabolism of allopurinol to ribonucleotides than L. braziliensis. 4-Aminopyrazolo(3,4-d)pyrimidine inhibited cell growth and resulted in high intracellular levels of 1-ribosyl allopurinol 5'-phosphate and smaller amounts of the 4-aminopyrazolo(3,4-d)pyrimidine ribonucleotides. The metabolism of allopurinol to 4-aminopyrazolo(3,4-d)pyrimidine ribonucleotides and its resultant cytotoxicity occurs in these parasitic protozoans, but not in mammalian cells.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 438170

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  Antileishmanial drug targeting through glycosylated polymers specifically internalized by macrophage membrane lectins.

Authors:  E Nègre; M L Chance; S Y Hanboula; M Monsigny; A C Roche; R M Mayer; M Hommel
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

2.  Nobel lecture in physiology or medicine--1988. The purine path to chemotherapy.

Authors:  G B Elion
Journal:  In Vitro Cell Dev Biol       Date:  1989-04

3.  Biological action of inosine analogs in Leishmania and Trypanosoma spp.

Authors:  J J Marr; R L Berens; N K Cohn; D J Nelson; R S Klein
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

4.  Purine nucleobase transport in amastigotes of Leishmania mexicana: involvement in allopurinol uptake.

Authors:  Mohammed I Al-Salabi; Harry P de Koning
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

5.  Comparative effects of 4-aminopyrazolopyrimidine, its 2'-deoxyriboside derivative, and allopurinol on in vitro growth of American Leishmania species.

Authors:  J L Avila; M A Casanova
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

6.  Nucleolar alterations induced by 4-aminopyrazolo(3,4-d)pyrimidine in adrenal cortex and liver cells of rat.

Authors:  H Almeida; M Magalhães; M C Magalhães
Journal:  Cell Tissue Res       Date:  1987-04       Impact factor: 5.249

7.  Effect of allopurinol on Trypanosoma cruzi: metabolism and biological activity in intracellular and bloodstream forms.

Authors:  R L Berens; J J Marr; F S Steele da Cruz; D J Nelson
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

8.  Effects of probenecid on the pharmacokinetics of allopurinol riboside.

Authors:  J B Were; T A Shapiro
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

9.  Pyrazolopyrimidine metabolism in parasitic protozoa.

Authors:  B Ullman
Journal:  Pharm Res       Date:  1984-09       Impact factor: 4.200

Review 10.  Target validation: linking target and chemical properties to desired product profile.

Authors:  Paul G Wyatt; Ian H Gilbert; Kevin D Read; Alan H Fairlamb
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.